Total Payments
$271,441
2024 Payments
$6,036
Companies
23
Transactions
147
Medicare Patients
41
Medicare Billing
$3,113
Payment Breakdown by Category
Consulting$198,077 (73.0%)
Other$26,964 (9.9%)
Research$26,805 (9.9%)
Travel$16,802 (6.2%)
Food & Beverage$2,792 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $198,077 | 56 | 73.0% |
| Unspecified | $26,805 | 11 | 9.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,082 | 8 | 8.1% |
| Travel and Lodging | $16,802 | 34 | 6.2% |
| Honoraria | $4,882 | 3 | 1.8% |
| Food and Beverage | $2,792 | 35 | 1.0% |
Payments by Type
General
$244,636
136 transactions
Research
$26,805
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Halozyme Inc | $47,199 | 27 | $0 (2019) |
| GENZYME CORPORATION | $39,035 | 19 | $0 (2024) |
| SANOFI US SERVICES INC. | $38,208 | 4 | $0 (2023) |
| Dova Pharmaceuticals | $33,859 | 17 | $0 (2021) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $26,887 | 9 | $0 (2023) |
| BIOVERATIV THERAPEUTICS INC. | $20,109 | 16 | $0 (2020) |
| SOBI, INC | $13,489 | 4 | $0 (2023) |
| Rigel Pharmaceuticals, Inc. | $8,785 | 12 | $0 (2020) |
| Boehringer Ingelheim International GmbH | $8,654 | 8 | $0 (2023) |
| ARGENX US, INC. | $8,400 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,036 | 5 | Pharmacosmos Therapeutics Inc. ($2,732) |
| 2023 | $57,939 | 13 | SANOFI US SERVICES INC. ($28,224) |
| 2022 | $44,991 | 21 | Novartis Pharmaceuticals Corporation ($9,601) |
| 2021 | $23,963 | 11 | Dova Pharmaceuticals ($6,080) |
| 2020 | $35,588 | 16 | BIOVERATIV THERAPEUTICS INC. ($10,471) |
| 2019 | $57,076 | 46 | Dova Pharmaceuticals ($18,790) |
| 2018 | $36,191 | 29 | Halozyme Inc ($25,200) |
| 2017 | $9,656 | 6 | Halozyme Inc ($9,561) |
All Payment Transactions
147 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $125.63 | General |
| Category: Rare Disease | ||||||
| 10/31/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Honoraria | In-kind items and services | $2,732.00 | General |
| Category: HEMATOLOGY | ||||||
| 07/11/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $105.40 | General |
| 05/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $580.00 | General |
| 04/23/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,493.00 | General |
| 12/06/2023 | ARGENX US, INC. | VYVGART HYTRULO (Drug), VYVGART | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Neurology | ||||||
| 11/10/2023 | GENZYME CORPORATION | — | Food and Beverage | Cash or cash equivalent | $114.64 | General |
| 11/10/2023 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $100.00 | General |
| 09/20/2023 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $17,248.00 | General |
| 07/13/2023 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $10,976.00 | General |
| 07/10/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $10,351.00 | General |
| 06/27/2023 | GENZYME CORPORATION | ENJAYMO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Hematology | ||||||
| 06/25/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $92.92 | General |
| 06/15/2023 | SOBI, INC | Doptelet (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,012.50 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/08/2023 | SOBI, INC | Doptelet (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/01/2023 | ARGENX US, INC. | VYVGART HYTRULO (Drug), VYVGART | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Neurology | ||||||
| 01/25/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,443.75 | General |
| 01/23/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | PROMACTA (Drug) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: Oncology | ||||||
| 12/16/2022 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $472.50 | General |
| 12/14/2022 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Immunology | ||||||
| 12/10/2022 | GENZYME CORPORATION | CABLIVI (Biological), ENJAYMO | Food and Beverage | In-kind items and services | $88.37 | General |
| Category: Hematology | ||||||
| 12/09/2022 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $127.49 | General |
| Category: ONCOLOGY | ||||||
| 12/01/2022 | ARGENX US, INC. | VYVGART (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Immunology | ||||||
| 11/07/2022 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| 07/14/2022 | Sobi, Inc | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $76.56 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects Wit | Halozyme Inc | $12,438 | 5 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | Halozyme Inc | $11,806 | 4 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant | Halozyme Inc | $2,561 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 13 | 20 | $5,440 | $872.59 |
| 2020 | 2 | 28 | 28 | $15,607 | $2,241 |
Total Patients
41
Total Services
48
Medicare Billing
$3,113
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 13 | 20 | $5,440 | $872.59 | 16.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 14 | 14 | $10,581 | $1,527 | 14.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 14 | 14 | $5,026 | $713.51 | 14.2% |
About Dr. Keith Mccrae, MD
Dr. Keith Mccrae, MD is a Hematology & Oncology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356367973.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Keith Mccrae, MD has received a total of $271,441 in payments from pharmaceutical and medical device companies, with $6,036 received in 2024. These payments were reported across 147 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($198,077).
As a Medicare-enrolled provider, Mccrae has provided services to 41 Medicare beneficiaries, totaling 48 services with total Medicare billing of $3,113. Data is available for 2 years (2020–2023), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Cleveland, OH
- Active Since 07/15/2006
- Last Updated 01/29/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356367973
Products in Payments
- Doptelet (Drug) $43,572
- PROMACTA (Drug) $23,743
- NO PRODUCT DISCUSSED (Drug) $9,638
- Hylenex (Drug) $9,617
- CABLIVI (Drug) $8,945
- Tavalisse (Drug) $8,785
- ENJAYMO (Biological) $8,446
- Nplate (Biological) $4,868
- VYVGART (Drug) $4,200
- VYVGART HYTRULO (Drug) $4,200
- DOPTELET (Drug) $3,777
- ELIQUIS (Drug) $3,753
- MONOFERRIC (Drug) $2,732
- Mulpleta (Drug) $1,717
- JARDIANCE (Drug) $525.00
- Soliris (Drug) $150.00
- ULTOMIRIS (Biological) $125.63
- CABLIVI (Biological) $88.37
- ANDEXXA (Biological) $63.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cleveland
Hillard Lazarus, Md, MD
Hematology & Oncology — Payments: $2.5M
Hematology & Oncology $2.5M
Jorge Garcia, Md, MD
Hematology & Oncology — Payments: $765,093
Hematology & Oncology $765,093
Ronald Bukowski, Md, MD
Hematology & Oncology — Payments: $744,876
Hematology & Oncology $744,876
Balazs Halmos, Md, MD
Hematology & Oncology — Payments: $548,525
Hematology & Oncology $548,525
Dr. Dale Shepard, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $481,414
Hematology & Oncology $481,414
Bachar Dergham, Md, MD
Hematology & Oncology — Payments: $456,653
Hematology & Oncology $456,653